An interventional study of zotarolimus-eluting stent (ENDEAVOR®) and sirolimus-eluting stents (CYPHER SELECT® PLUS) in Coronary Artery Disease and Atherosclerosis, sponsored by Hyogo Medical University. Withdrawn at 1 site in Japan. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-03.
Sponsored by Hyogo Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.
Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 100th largest by enrollment of the 100 interventional ones that give a count, is one of 19 that started in 2010, is one of 39 with no phase, and was the 26th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, United States, Australia and 2 more countries
Ages 18–80
Medtronic Vascular · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
CSL Behring · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
Seung-Jung Park · Sites in Japan, Hong Kong, India and 2 more countries
Ages 20+
Weill Medical College of Cornell University · Sites in Japan, United States, Australia and 23 more countries
Ages 18+ · Women only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 25 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 36
First in 1996; this study’s year is marked. 19 started in 2010.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 445 across the 100 interventional studies, 431 across the 34 observational. Of the 91 that completed or were terminated, 36 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
Hyogo Medical University is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Hyogo Medical University has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
| NCT07830719Novartis PharmaceuticalsDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | 2027-08-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 134 studies in Coronary Artery Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: zotarolimus-eluting stent (ENDEAVOR®)
Device: sirolimus-eluting stents (CYPHER SELECT® PLUS)
Device: everolimus-eluting stents (PROMUS®)
zotarolimus-eluting stent
sirolimus-eluting stents
everolimus-eluting stents
To compare coronary endothelial function after primary angioplasty.
Time frame: 6 months and 12 months
To compare the presence of neointimal stent strut coverage via optical coherence tomography.
Time frame: 6 months and 12 months
To compare the serum biomarker levels measured in coronary artery blood.
Time frame: 6 months and 12 months
The record gives a start of Apr 2010, a primary completion of Oct 2011 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyogo Medical University